康乐卫士发行费用总额为2,737.59万元（超额配售选择权行使前）；3,008.02万元（若超额配售选择 权全额行使后），其中中信证券、国信证券获得承销保荐费1,902.83万元（超额配售选择权行使前）； 2,173.25万元（超额配售选择权全额行使后）。 2023年5月17日，康乐卫士公告分红方案，每10股转增10股，除权除息日为2023年5月26日。 (责任编辑：关婧) 中国经济网北京12月31日讯 康乐卫士(920575.BJ)今日收报8.27元，跌幅4.83%。目前该股处于破发 状态。 康乐卫士于2023年3月15日在北交所上市，发行价为42.00元，该股上市首日开盘破发，首日收盘报 35.52元，跌幅15.43%。 康乐卫士在北交所发行数量7,000,000股（不含超额配售选择权）；8,050,000股（全额行使超额配售 选择权后），保荐机构（主承销商）为中信证券股份有限公司，保荐代表人胡朝峰、赵洞天，联席主承 销商为国信证券股份有限公司。 超额配售选择权行使前，康乐卫士募集资金总额为29,400.00万元，扣除发行费用2,737.59万元（不 含增值税）后，募集资金净额为26,662.41万元。公 ...

从资金流向上来看，当日生物制品板块主力资金净流出1.85亿元，游资资金净流入8362.31万元，散户资 金净流入1.01亿元。生物制品板块个股资金流向见下表： 证券之星消息，12月31日生物制品板块较上一交易日下跌0.27%，康乐卫士领跌。当日上证指数报收于 3968.84，上涨0.09%。深证成指报收于13525.02，下跌0.58%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920047 | 诺思兰德 | 23.71 | 2.46% | 3.54万 | | 8429.48万 | | 301080 | 百普赛斯 | 54.00 | 2.39% | 1.16万 | | 6168.09万 | | 688488 | 文曲药业 | 16.33 | 2.19% | 9.07万 | | 1.49亿 | | 603087 | 甘李药业 | 68.07 | 1.66% | 1 7.32万 | | 4.97亿 | | 688293 | 奥浦迈 | 49.00 ...

Core Viewpoint - Kangla Weishi, once hailed as the "first stock of the North Exchange vaccine," is currently facing a liquidity crisis due to a loan default and multiple lawsuits, raising concerns about its financial stability and long-term development challenges [1][2]. Financial Performance - The company has not achieved commercialization of its core products, relying on minimal revenue from research testing reagents and property services, leading to a significant revenue decline [2][5]. - In 2023, the total revenue was 1.78 million yuan, which dropped by 50.24% to 0.89 million yuan in 2024, while in the first three quarters of 2025, revenue slightly improved to 1.28 million yuan, a year-on-year increase of 106.53% [4][5]. - The net profit attributable to shareholders showed a loss of 3.01 billion yuan in 2023, worsening to 3.57 billion yuan in 2024, but narrowed to 2.29 billion yuan in the first three quarters of 2025, indicating a 16.60% improvement [5][6]. Cash Flow and Expenses - The company has been experiencing negative operating cash flow, with a net cash flow from operating activities of -75.67 million yuan in the first three quarters of 2025, despite a slight improvement [7]. - High R&D expenses, which reached 254 million yuan in 2024, have further strained the company's finances, as total operating costs were 364 million yuan against a revenue of only 0.89 million yuan [7][8]. Liquidity Crisis - The liquidity crisis is attributed to the company's over-reliance on external financing, as evidenced by extensive collateral arrangements for loans, indicating a lack of sufficient liquidity at the time of borrowing [9][12]. - The company is also facing multiple lawsuits totaling 30.86 million yuan, which adds to its financial burdens and operational challenges [12]. Product Development and Commercialization - Despite the financial difficulties, the company is making progress in the development of its core HPV vaccine products, with the three-valent HPV vaccine's application for market approval being processed [13][14]. - The company is preparing for a dual listing in Hong Kong to improve its financial situation, although the progress of this IPO remains uncertain due to the recent liquidity crisis [15].

Core Viewpoint - The company Kang Le Wei Zhi is facing significant liquidity pressure due to ongoing R&D investments and delays in financing, leading to multiple court-ordered consumption restrictions and frozen bank accounts [2][3][4]. Financial Situation - As of December 26, 2025, Kang Le Wei Zhi's total market capitalization was 2.512 billion yuan [2]. - The company reported a net loss of 3.57 billion yuan for the year 2024, with a net asset deficit of 1.686 billion yuan [8]. - By the end of 2024, the company's current liabilities exceeded current assets by 7.32 billion yuan [8]. - For the first three quarters of 2025, the company generated revenue of 127.63 million yuan, with a net loss of 2.29 billion yuan [9]. Legal and Operational Challenges - The company and its legal representative, Tao Ran, have been subjected to multiple consumption restriction orders due to failure to fulfill financial obligations, with amounts involved totaling 19.85 million yuan, 6.6 million yuan, and 7.86 million yuan [3][4]. - As of December 18, 2025, 15 bank accounts belonging to the company and its subsidiaries were frozen, representing 41.67% of their total accounts, with a cumulative frozen amount of 346,900 yuan [5]. R&D and Market Position - Kang Le Wei Zhi specializes in HPV vaccines, with ongoing clinical trials for various products, including a nine-valent HPV vaccine and a fifteen-valent HPV vaccine in collaboration with Chengda Biological [6]. - The HPV vaccine market is highly competitive, with several established players and a decline in vaccine prices due to increased supply [7]. - The company has not yet launched any vaccine products, and its revenue primarily comes from the sale of research reagents, which is relatively small [7]. Future Outlook - The company has submitted an application for a Hong Kong stock listing, but there has been no recent progress [6]. - The inclusion of HPV vaccines in the national immunization program starting November 10, 2025, may intensify competition for Kang Le Wei Zhi's products [7].

近日，北交所上市公司康乐卫士发布的一则公告，将其深陷的债务、诉讼与经营困境暴露于公众视野。 这家曾顶着"国产9价HPV疫苗"光环、一度受资本热捧的生物科技公司，如今正面临银行贷款违约、账 户冻结、员工离职、研发放缓等多重压力，其背后折射出Biotech企业在产品商业化前常见的资金枯竭 困局，以及HPV疫苗市场环境的急剧变化。 一、资金链断裂：贷款违约、账户冻结、诉讼缠身 公告显示，康乐卫士控股子公司昆明康乐未能按期偿还中信银行昆明分行的贷款本息，剩余未还金额达 1521.17万元。虽然数额不大，但违约行为已触发连锁风险——担保物涉及公司土地、设备、应收账 款、股权乃至实控人股票，一旦债务无法化解，可能导致资产被处置、股权变动，进一步损害公司信用 与融资能力。 康乐卫士的主打产品——三价及九价HPV疫苗，仍处于临床研究或资料补充阶段，尚未获批上市。然而 市场已今非昔比。 一度"一苗难求"的九价HPV疫苗，如今销售增速放缓。行业龙头智飞生物2024年营收与净利润双双大幅 下滑，存货飙升至222.69亿元，坦言"经营困难"。与此同时，二价HPV疫苗在集采与竞争加剧背景下， 价格从每支329元骤降至30元以下，显示H ...

Core Viewpoint - Beijing Kanglwei Biological Technology Co., Ltd. (Kanglwei) announced that its subsidiary, Kunming Kanglwei, failed to repay a loan of 15.21 million yuan from CITIC Bank but has since settled the debt in full [1] Financial Performance - As of September 2025, Kanglwei's consolidated asset-liability ratio was approximately 78.36%, an increase of 14.16% from 64.20% at the end of 2024 [1] - Current non-current liabilities due within one year amounted to approximately 96.49 million yuan, reflecting a change of 64.75% [1] - Long-term borrowings were approximately 17.28 million yuan, showing a decrease of 81.06% [1] - Lease liabilities were approximately 0.29 million yuan, with a change of -90.91% [1] Company Overview - Established in 2008, Kanglwei is a high-tech enterprise focused on innovative vaccine research and commercialization [2] - The company is a leader in HPV vaccine development in China, offering a comprehensive product portfolio that includes three-valent, nine-valent, and fifteen-valent HPV vaccines [2] - As of September, Kanglwei's R&D expenses accounted for approximately 9263.76% of total operating income, the highest among companies listed on the Beijing Stock Exchange [2]

康乐卫士彼时表示，公司部分银行账户被冻结，对日常经营的资金周转与支付造成一定影响。公司正积 极与相关方及司法机关沟通，争取通过协商和解等方式尽快解冻账户，以降低该事项对公司正常生产经 营的不利影响。本次被冻结的账户中包含一个北交所公开发行募集资金专户，冻结金额为2.79元（全部 为募集资金利息），冻结金额较小。除部分银行账户已被冻结外，公司的一项专利同样因为劳动仲裁案 件被采取财产保全措施。公司目前尚未实现商业化，营运资金主要来源于外部融资。因持续研发投入及 融资进度未及预期，公司面临阶段性流动性压力。 北京商报讯（记者 丁宁）康乐卫士（920575）近期公告称，公司控股子公司康乐卫士（昆明）生物技 术有限公司（以下简称"昆明康乐"）尚未按期偿还中信银行股份有限公司昆明分行的贷款金额1521.17 万元。12月19日，康乐卫士披露的公告显示，昆明康乐已完成上述银行贷款的偿还，本息已全部结清。 康乐卫士表示，公司及子公司正努力通过多渠道筹措资金，加强资金管理，努力保障后续银行贷款的按 期偿还。同时，公司将采取一切必要措施，全力支持核心业务的稳定运营，改善公司整体经营状况。 值得一提的是，据康乐卫士此前公告，公司 ...

2023年5月17日，康乐卫士公告分红方案，每10股转增10股，除权除息日为2023年5月26日。 (责任编辑：魏京婷) 康乐卫士在北交所发行数量7,000,000股（不含超额配售选择权）；8,050,000股（全额行使超额配售 选择权后），保荐机构（主承销商）为中信证券股份有限公司，保荐代表人胡朝峰、赵洞天，联席主承 销商为国信证券股份有限公司。 超额配售选择权行使前，康乐卫士募集资金总额为29,400.00万元，扣除发行费用2,737.59万元（不 含增值税）后，募集资金净额为26,662.41万元。公司募集资金净额比原计划少3,337.59万元。2023年2月 28日公司招股书显示，康乐卫士拟募集资金30,000.00万元，用于HPV疫苗研发项目、昆明生产基地代建 回购项目。 康乐卫士发行费用总额为2,737.59万元（超额配售选择权行使前）；3,008.02万元（若超额配售选择 权全额行使后），其中中信证券、国信证券获得承销保荐费1,902.83万元（超额配售选择权行使前）； 2,173.25万元（超额配售选择权全额行使后）。 中国经济网北京12月19日讯 康乐卫士(920575.BJ)今日收报8.6 ...

证券日报网讯 12月18日晚间，康乐卫士发布公告称，聘任王泽学先生为公司首席财务官。 （文章来源：证券日报） ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002880 | 卫光生物 | 25.31 | -1.02% | 7083.18 | 1790.31万 | | 002252 | 十件與上 | 6.36 | -0.47% | 26.50万 | 1.68亿 | | 301393 | 吴帆生物 | 49.17 | -0.45% | 1.01万 | 4922.42万 | | 688670 | 金迪克 | 22.19 | -0.31% | 4.31万 | 9611.75万 | | 301080 | 百普赛斯 | 52.13 | -0.29% | 2.41万 | 1.24亿 | | 000661 | 长春高新 | 95.31 | -0.23% | 7.81万 | 7.35亿 | | 300239 | 东宝生物 | 5.27 | -0.19% | 9.38万 | 4908.25万 | | 300318 | 博晖创新 | 6.24 | -0.16% | 10.33万 | 6417.65万 | | 688105 ...